Difficulty: Medium
Average Score: 63%
Practice
Which of the following drugs has the LONGEST duration of action in a patient with renal failure?
Correct answer
A
Rationale
In the context of basic post-operative care for a patient with renal failure, understanding the pharmacokinetics of drugs used for anesthesia is crucial. Neostigmine, the correct answer, has the longest duration of action among the options provided.
Neostigmine is a cholinesterase inhibitor that reverses neuromuscular blockade by inhibiting acetylcholinesterase, leading to increased levels of acetylcholine at the neuromuscular junction. In renal failure, drugs like neostigmine are not renally cleared, unlike most neuromuscular blocking agents. This results in a prolonged duration of action in patients with impaired renal function.
Rocuronium, succinylcholine, and vecuronium, the incorrect options, are neuromuscular blocking agents that are primarily eliminated through renal excretion. In renal failure, the clearance of these drugs is reduced, leading to a shorter duration of action due to their accumulation in the body.
Educationally, this question emphasizes the importance of considering altered pharmacokinetics in patients with renal impairment when selecting medications, especially in the post-operative setting. It highlights the need for healthcare providers to individualize drug therapy based on a patient's renal function to optimize outcomes and prevent adverse effects.
Neostigmine is a cholinesterase inhibitor that reverses neuromuscular blockade by inhibiting acetylcholinesterase, leading to increased levels of acetylcholine at the neuromuscular junction. In renal failure, drugs like neostigmine are not renally cleared, unlike most neuromuscular blocking agents. This results in a prolonged duration of action in patients with impaired renal function.
Rocuronium, succinylcholine, and vecuronium, the incorrect options, are neuromuscular blocking agents that are primarily eliminated through renal excretion. In renal failure, the clearance of these drugs is reduced, leading to a shorter duration of action due to their accumulation in the body.
Educationally, this question emphasizes the importance of considering altered pharmacokinetics in patients with renal impairment when selecting medications, especially in the post-operative setting. It highlights the need for healthcare providers to individualize drug therapy based on a patient's renal function to optimize outcomes and prevent adverse effects.